Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran

Elnaz Amanollahi Kamaneh, M.Sc.1, Karim Shams Asenjan, Ph.D.1*, Aliakbar Movassaghpour Akbari, Ph.D.1, Parvin Akbarzadeh Laleh, Ph.D.1, Hadi Chavoshi, M.D.1, Jamal Eivazi Ziaei, M.D.1, Alireza Nikanfar, M.D.1, Iraj Asvadi Kermani, M.D.1, Ali Esfahani, M.D.1

1. Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

*Corresponding Address: P.O.Box: 51667-697997, Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Email: k.shams@ibto.ir

Received: 17/Jun/2015, Accepted: 4/Aug/2015

Abstract

Objective: Detection of chromosomal translocations has an important role in diagnosis and treatment of hematological disorders. We aimed to evaluate the 46 new cases of de novo acute myeloid leukemia (AML) patients for common translocations and to assess the effect of geographic and ethnic differences on their frequencies.

Materials and Methods: In this descriptive study, reverse transcriptase-polymerase chain reaction (RT-PCR) was used on 46 fresh bone marrow or peripheral blood samples to detect translocations t (8; 21), t (15; 17), t (9; 11) and inv (16). Patients were classified using the French-American-British (FAB) criteria in to eight sub-groups (M0-M7). Immunophenotyping and biochemical test results of patients were compared with RT-PCR results.

Results: Our patients were relatively young with a mean age of 44 years. AML was relatively predominant in female patients (54.3%) and most of patients belonged to AML-M2. Translocation t (8; 21) had the highest frequency (13%) and t (15; 17) with 2.7% incidence was the second most frequent. CD19 as an immunophenotypic marker was at a relatively high frequency (50%) in cases with t (8; 21), and patients with this translocation had a specific immunophenotypic pattern of complete expression of CD45, CD38, CD34, CD33 and HLA-DR.

Conclusion: Similarities and differences of results in Iran with different parts of the world can be explained with ethnic and geographic factors in characterizations of AML. Recognition of these factors especially in other comprehensive studies may aid better diagnosis and management of this disease.

Keywords: Chromosomal Translocation, Acute Myeloid Leukemia, Iran

Introduction

Chromosomal translocations have a significant role in the initiation of carcinogenesis by creating gene fusions that are causal for approximately 20% of human cancers (1, 2). So far, many gene fusions have been recognized that have important diagnostic and prognostic roles in malignant hematological disorders of which some are leukemia-associated markers for minimal residual disease (MRD) detection (2-4). Acute myeloid leukemia (AML) constitues less than 1% of all cancers and 25% of all leukemia cases. It is more common in adults and its prevalence increases with age (5).

It was estimated that among 52,380 new cases of leukemia in the United States in 2014, 18,860 (36%) of them were AML cases, and among 24,090 estimated leukemia deaths, 10, 460 (43%)...
Chromosomal Translocations in AML

instances were due to AML (6). Balanced chromosomal rearrangements, in particular translocations, occur in 25 to 30% of AML cases. Because of their importance in recognizing genes involved in leukemogenesis and their relation with the treatment of patients, it has received much attention (7).

In AML, gene fusions often encode specific oncoprotein fusion proteins. Four most common rearrangements in AML include t (15; 17), t (8; 21), inv (16) and 11q23/MLL and have frequencies between 3 and 10%. These translocations respectively encode PML-RARA, AML1-ETO, CBFB-MYH11 and MLL-fusions oncoprotein fusion proteins (8). Translocation t (8; 21) has a close relation with the AML-M2 subgroup in FAB classification and is mostly present in patients in this subgroup and rarely in M1 and M4 subgroups (9). The t (15; 17) translocation is found in about 95% of acute promyelocytic leukemia (APL), which is treatable in its early phase with all-trans retinoic acid (ATRA) (8, 10, 11).

Molecular cytogenetic analysis, compared with classical cytogenetic analysis, has many advantages including rapid and comprehensive detection of known target translocations. Reverse transcriptase-polymerase chain reaction (RT-PCR) is a fast and sensitive technique that can be used on small samples with low quality (12-15).

Given the importance of knowing the prevalence of chromosomal aberrations and their specific phenotypes in certain geographic region or ethnicity, for rapid diagnosis and best treatment selection, we aimed to evaluate the frequency of four common chromosomal translocations among 46 de novo AML patients.

Materials and Methods

Patient selection

In this descriptive study, 46 new cases of adult de novo AML who were diagnosed in Shahid Ghazi hospital (Tabriz, Iran) from 2012-2014 were included. AML diagnosis was confirmed by bone marrow aspiration and peripheral blood smears, total blood count, cytochemistry and immunophenotyping. Two independent oncologists classified patients based on the French-American-British (FAB) Cooperative Group criteria in eight subtypes (M0-M7). Cases with past clinical history and those who had received any treatment were excluded.

Bone marrow aspiration collection

Aspiration specimens were collected in tubes with Ethylenediaminetetraacetic acid (EDTA, Merck, Germany) anticoagulant and transferred to the laboratory at 4°C within 8 hours. In three cases in which aspiration was impossible, on the condition that we had enough blast cells, peripheral blood samples were collected.

Mononuclear cell isolation

Mononuclear cells were isolated within 24 hours after sample collection. The white blood cell (WBC) count was adjusted to less than 20×10⁷/ml by diluting specimens in phosphate-buffered saline (PBS, Sigma, USA). For cell isolation, we used Ficol (Baharafshan, Iran) and after collection of the mononuclear cell layer, cells were washed with 10 ml PBS containing 10% fetal bovine serum (FBS, Gibco, USA). The supernatant was removed after centrifugation (Sigma, USA), and 1 ml of Qiazol (Qiagen, USA) was then added to the cell precipitate to dissolve cells completely. This solution was stored in -70°C, until RNA extraction.

Total RNA extraction

Frozen samples were thawed at room temperature and mixed. Next 200 µl cold chloroform (Merck, Germany) was added to 1 ml of this solution and mixed and incubated in room temperature for 2 minutes. The solution was then centrifuged (Sigma, USA) at 4°C and 18000 rpm for 30 minutes.

Four- to five hundred micro liter of aqueous phase was transferred into another microtube on ice and then 500-600 µl cold isopropanol (100%) (Merck, Germany) was added. After mixing, the solution was incubated on ice for 10-15 minutes and then centrifuged at 4°C and 18000 rpm for 20 minutes.

After removing the supernatant, 0.5-1 ml, cold ethanol (Scharlau, Sentmenat, Spain) (75% in DEPC- treated water) was added to the precipitate and agitated gently. Finally it was centrifuged at 4°C and 18000 rpm for 5 minutes. This washing process was repeated to acquire best results.

Then supernatant was discarded gently and microtubes were placed at room temperature to dry the RNA. Afterwards, microtubes were placed on ice and 50 µl DEPC-treated water (CinnaGen, Iran) was added to them with mixing. Pico drop (Pico drop Ltd, UK) was used to estimate the RNA concentration. Integrity of isolated RNA was analyzed indirectly by the quality of synthesized complementary DNA (cDNA).
cDNA synthesis

Reverse transcription reaction was done according to the BioRT cDNA first strand synthesis kit protocol (Bioer Technology, Japan).

Reverse transcriptase-polymerase chain reaction analysis

Primers used for the four common fusion transcripts of chromosomal translocations are given in Table 1. To assess presence of *AML1-ETO*, *PML-RARA* and *CBFB-MYH11*, final volume of PCR was 10 µl with 4 µl Master Mix, 4.5 µl dH2O, 0.5 µl cDNA and 0.5 µl of each primer (20 pmol/µl). PCR conditions were an initial denaturation step at 94°C for 3 minutes, followed by 35 cycles at 94°C for 45 seconds, 63°C for 1 minute and 72°C for 1.5 minutes. Final extension step was 72°C for 7 minutes (16).

For the *MLL-AF9* fusion transcript, all quantities remained the same. In this group initial denaturation step was at 94°C for 5 minutes, followed by 35 cycles at 94°C for 1 minute, 60°C for 1 minute and 72°C for 1 minute. The time of the final extension step also increased to 10 minutes (17).

The PCR products were analyzed on 2% agarose gel electrophoresis. We used confirmed positive patients samples from another source as positive controls. The blank control without cDNA was used in each run.

Immunophenotyping

Specimens (bone marrow aspiration or peripheral blood) were collected separately in tubes with EDTA for immunophenotyping. After cell counting with the automatic analyzer (H1, Tecknicon, USA), cells were washed with PBS twice and cell count was then adjusted to 10-20×10^6/ml.

Our samples were first analyzed by a flow cytometer (BD FACS Calibur, Becton Dickinson, USA). Samples were then stained directly with fluorochrome-conjugated antibodies (DAKO, Denmark). We used the following antibodies according to the applied protocol (BD FACS): CD45-FITC for gating strategies, CD13-PE, CD14-PE, CD15-FITC, CD33-PE, CD41-FITC, CD 117-PE and GpA-FITC for myeloid line-specific antigens, CD2-PE, CD3-FITC, CD7-FITC, CD19-PE, CD20- FITC and CD22-PE for lymphoid line-specific antigens, CD34-PE, CD38-PE, HLA-DR-FITC and CD10-FITC for determination of maturation stage and CD11b-FITC for non-line-specific antigen. Data were analyzed with Cell quest (BD, USA), and positivity threshold for each monoclonal antibody was defined as 20% labeled cells.

Biochemical analysis

We obtained biochemical test results of each patient that is undertaken routinely for all leukemia patients with an auto analyzer (Alesion, Abbott, Germany).

| Fusion transcripts | Primers 5’−→3’ | Size of PCR products(bp) |
|--------------------|----------------|-------------------------|
| *AML1*             | CTACCGCAGCCATGAAGAACC | 395                    |
| *ETO*              | AGAGGAAGGCCCATGCTGAA |                        |
| *PML*              | CAGTGTAACGCTTTCTCCATCA | 381                    |
| *RARA*             | GCTTGATAGTGCGGGGTAGA |                        |
| *CBFB*             | GCAGGCAAGGTATATTTGAAGG | 418                    |
| *MYH11*            | TCTCTCTCTCCTCTCCATGTC |                        |
| *MLL(3920U)*       | CTCAGCCACCTACTACAGGAC | 852                    |
| *AF9(1645L)*       | AGCGGAGCAAGATCAAATC  |                        |

PCR; Polymerase chain reaction.
Chromosomal Translocations in AML

Statistical analysis

SPSS version 21 (IBM, USA) was used for all statistical analysis. Descriptive statistics were used to describe the variables. Independent t test was used for analysis of relationship between biochemical results and prevalence of t (8; 21). A P value less than 0.05 was considered statistically significant.

Ethical consideration

The Ethics Committee of the Tabriz University of Medical Sciences approved this study. Samples were collected after obtaining informed consent from each patient.

Results

Frequency of the four common chromosomal translocations

Among the 46 patients, six patients (13%) were positive for AML1-ETO (Fig.1) and one (2.7%) for PML-RARA (Fig.2). Other fusion transcripts (CBFB-MYH11 and MLL-AF9) were absent in all patients (data was not shown).

Clinical characteristics

Summary of clinical, hematological and phenotypic characteristics of all AML patients are reported in Table 2 and specific characteristics of t (8; 21) positive patients are reported in Table 3.

Recently morphologic FAB classification of four t (8; 21) positive patients revised and approved again, but for the other two patients, smears were not available.

The patient who was positive for t (15; 17) was a non-smoking 44 year-old male. His FAB classification was M3 with B positive blood group. His white blood cell count was 33.84×10^3 /µl and his platelet count was 21×10^3 /µl with 4.9 g/dl hemoglobin and 20% blasts in the first peripheral blood test.

Immunophenotypic characteristics

Frequency of some immunophenotypic antigens in the total AML sample set were: CD45: 100%, CD33: 97.9%, CD38: 95.7%, CD13: 82.6%, HLA-DR: 65.2%, CD117: 63%, CD11b: 60.9%, CD34: 54.3%, CD14: 15.2%, CD15: 28.3% GpA: 6.5% and CD19: 8.7%.

Immunophenotypic information for patients with t (8; 21) are given in Table 4. Our t (15, 17) positive patient had the following immunophenotypic
characteristics: CD13: 80%, CD14: 39%, CD33: 76%, CD11b: 27%, CD45: 94% and CD38: 76% with all other (especially CD34 and HLA-DR) being negative.

**Expression of CD19 at t (8; 21)**

The relation between CD19 expression and t (8; 21) has previously been reported (18, 19). Expression of CD19 in our t (8; 21) positive patients was 50% but it showed 2.5% expression in patients that were negative for this translocation. However, since the number of positive patients was small, this finding was not statistically significant.

**Biochemical results of positive translocation patients**

Results of common biochemical tests for t (8; 21) positive patients are reported in Table 5. We observed no relation between these results and the occurrence of translocation.

| Table 2: Summary of clinical, hematologic and morphologic characteristics for total acute myeloid leukemia patients |
|---------------------------------------------------------------|
| **n (%)** | **Mean (SD)** | **Range (minimum-maximum)** |
| Age | 44 (16.59) | 64 (16-80) |
| Male/Female | 21 (45.7%)/25 (54.3%) | |
| FAB | | |
| M0 | 1 (2.2%) | |
| M1 | 5 (10.9%) | |
| M2 | 16 (34.7%) | |
| M3 | 4 (8.7%) | |
| M4 | 8 (17.4%) | |
| M5 | 4 (8.7%) | |
| M7 | 1 (2.2%) | |
| Unknown | 7 (15.2%) | |
| Total | 46 (100%) | |
| WBC (<10³/µl) | 35.65 (49.19) | 201.43 (0.57-202) |
| Hb (g/dl) | 8.5 (1.68) | 6.7 (4.9-11.6) |
| PLT (<10³/µl) | 73.08 (92.97) | 493 (12-505) |
| Blast (%) | 28.14 (20.03) | 85 (3-88) |

FAB; French-American-British type, WBC; White blood cell, Hb; Hemoglobin and PLT; Platelet .

| Table 3: Clinical, hematologic and morphologic characteristics for six patients with t (8; 21) positive acute myeloid leukemia |
|---------------------------------------------------------------|
| **Case number** | 1 | 2 | 3 | 4 | 5 | 6 |
| Sex | M | F | F | M | M | M |
| Age | 25 | 33 | 16 | 58 | 59 | 54 |
| Familial history | N | N | N | N | N | N |
| Smoking | N | N | N | N | Pos | N |
| WBC (<10³/µl) | 36.12 | 5.64 | 6.81 | 55.75 | 8.58 | 12.67 |
| PLT (<10³/µl) | 14 | 17 | 14 | 12 | 26 | 14 |
| Hb (g/dl) | 6.3 | 9.4 | 10.1 | 9 | 7.4 | 8 |
| Blast (%) | 19 | 28 | 33 | 56 | 32 | 45 |
| Blood group | A+ | AB+ | O+ | O+ | A+ | A+ |
| FAB | M2 | M2 | M2 | M2 | M4 | M2 |

M; Male, F; Female, N; Negative, Pos; Positive, WBC; White blood cell, Hb; Hemoglobin, PLT; Platelet and FAB; French-American-British type.
### Table 4: Immunophenotypic analysis of six patients with t (8; 21) positive acute myeloid leukemia

| Case number | 1  | 2  | 3  | 4  | 5  | 6  |
|-------------|----|----|----|----|----|----|
| CD45        | 91 | 92 | 95 | 98 | 98 | 99 |
| CD38        | 90 | 90 | 98 | 98 | 86 | 100|
| CD33        | 81 | 74 | 65 | 82 | 89 | 50 |
| CD34        | 70 | 61 | 88 | 47 | 31 | 71 |
| HLA-DR      | 35 | 79 | 95 | 50 | 52 | 94 |
| CD13        | N  | 13 | 85 | 83 | 45 | 96 |
| CD117       | 70 | 73 | 88 | 44 | N  | N  |
| CD11b       | 38 | 15 | 18 | 32 | 69 | 6  |
| CD15        | N  | 8  | N  | 20 | 96 | N  |
| CD19        | 48 | N  | N  | 42 | N  | 97 |
| CD14        | 9  | N  | N  | 7  | 11 | N  |
| GpA         | N  | N  | N  | N  | N  | N  |
| CD41        | N  | N  | N  | N  | N  | N  |
| CD10        | N  | N  | N  | N  | N  | N  |
| CD7         | N  | N  | N  | N  | N  | N  |
| CD3         | N  | N  | N  | N  | N  | N  |
| CD2         | N  | N  | N  | N  | N  | N  |
| CD22        | N  | N  | N  | N  | N  | N  |
| CD20        | N  | N  | N  | N  | N  | N  |

GPA: Glycophorin A; N: Negative and *: Data are given as percentages.

### Table 5: Biochemical test results for six patients with t (8; 21) positive acute myeloid leukemia

| Case number | 1  | 2  | 3  | 4  | 5  | 6  |
|-------------|----|----|----|----|----|----|
| LDH (U/L)   | 4160 | ND | 728 | 2437 | ND | 1894 |
| Urea (mg/dl)| 32  | 28 | 21.4 | 39  | 28.1 | 34  |
| Creatinin (mg/dl)| ND | 0.39 | 0.43 | 0.96 | 0.85 | 1.29 |
| SGOT (U/L)  | 144 | 27 | 14  | 43  | 13  | 22  |
| SGPT (U/L)  | 254 | 91 | 10  | 37  | 183 | 15  |
| ALP (U/L)   | ND  | 151 | 224 | 165 | ND  | 148 |
| Uric Acid (mg/dl)| 6.2 | ND | 2.4 | 4.5 | ND  | 6.8 |
| FBS (mg/dl) | 117 | ND | ND  | ND  | 98  | 114 |

LDH: Lactate dehydrogenase, SGOT: Serum glutamic oxaloacetic transaminase, SGPT: Serum glutamic-pyruvic transaminase, ALP: Alkaline phosphatase, FBS: Fasting blood sugar and ND: Not done.
Discussion

Acute myeloid leukemia is a clonal heterogeneous disorder of hematopoietic progenitor cells that is most common in adults (20). Presence of recurrent chromosome abnormalities alone, such as t (8; 21), t (15; 17) and inv (16), is sufficient to diagnose AML (21). Diagnosis of chromosomal abnormalities may help to recognize cause of leukemogenesis and provide new strategies for treatment of patients (22). Geographic differences of chromosomal abnormalities in hematological disorders have been previously described (23, 24). In one report annual incidence of leukemia in Tabriz (largest city in Northwest of Iran) was 3.7 per 100,000 and incidence of AML in Northwest of Iran was 1.37 per 100,000 (25). There is a lack of information about the cytogenetic patterns of AML patients from many parts of the world and even in Iran where cytogenetic distribution in various ethnicities in different regions is unknown.

In this study, mean age of de novo AML patients was 44 years which is relatively similar to that of Malaysian patients (39 years) (26) but different to that in western countries (71 years) (27). The frequency of AML M2 (34.7%) was higher than any other subgroup and its frequency is comparable to that in Germany (39.6%) (28), USA (37%) (29), China (29.9%) (30), Taiwan (53%) (31), Korea (48.3%) (32), Hong Kong (50%) (33) and Malaysia (33.3%) (34). After that, M4 and M1 were the most frequent with 17.4 and 10.9% of patients respectively. AML M4 had a lower frequency than Germany (20.4%) (28) and USA (23%) (29) but a higher frequency compared with China (5.3%) (30), Taiwan (10%) (31), and Hong Kong (13.3%) (33). AML M3 (8.7%) has a relatively higher frequency compared with Germany (5%) (28) and USA (2%) (29), and it is lower than China (25.3%) (30), Taiwan (20%) (31), Korea (20.7%) (32), Hong Kong (20%) (33).

In a study of patients in Northeast of Iran, M4 had the highest frequency (24.58%), and then M1 (20.67%) M2 (17.88%) and M3 (16.76%) had the highest frequencies (35). However, in another study in Iran (based in Tehran), results were different with M2=34%, M3=33%, M1=24% and M4=5% (36).

AML distribution in our female patients (54.3%) was relatively higher than males. Translocation t (8; 21) has 13% frequency among AML patients. This is higher than Malaysia (7.5%) (26), China (8.3%) (30), USA (6%) (29), German study (4.3%) (28) and Northeast of Iran (8.9%) (35) but lower than Tehran-Iran (25.9%) (36), Korea (34.5%) (32) and Taiwan (23%) (31). Frequency of t (8; 21) in our M2 subgroup was 31.2% and comparable with Japan (33.1%) (23) and Malaysia (37.5%) (34) but higher than Australia (15.3%) (23) and Hong Kong (13.3%) (33). This frequency was lower than that of Northeast of Iran (50%) (35), Tehran-Iran (75%) (36) and Taiwan (43.7%) (31). All these different presentations of t (8; 21) may be due to different ethnicities in different geographic regions but more research with high number of patients is needed. The age of translocation t (8; 21) positive patients was under 60 years which is similar to most studies like in China and America. Moreover, all of these patients had anemia and thrombocytopenia.

Translocation t (15; 17) had a lower frequency (2.17%) and this is comparable to Malaysia (2.3%) (26) and USA (7%) (29) but lower than China (14.3%) (30) and Tehran-Iran (27%) (36). We had some limitations in confirming our M3 FAB classification, because bone marrow aspiration was impossible in some of them, even for immunophenotyping. Some patients expired very soon even in the first week. In some patients, blood or bone marrow smears were not available for revision. Finally in some of them immunophenotype, morphology and pathology results were contradictory. Because of these limitations, further comprehensive studies with all variant translocations in this subgroup are essential.

Results for inv (16) and t (9; 11) were negative in our study and this is may be because of low frequency of these abnormalities around the world and for better investigation, higher number of cases is needed (7, 8).

All of our patients were positive for the CD45 immunophenotypic marker, and myeloid specific markers (CD13 and CD33) had the highest percentage. All our t (8; 21) positive patients had a specific immunophenotypic pattern and strongly expressed CD45, CD38, CD34, CD33 and HLA-DR with 100% frequency. Among aberrant antigens, CD19 was expressed with 50% frequency. This is comparable with that in Australia (57.1%) and Japan (71.9%) (23). This is also in accordance
with studies that have established expression of B cell lineage genes such as CD19 and PAX5 as hallmarks of t (8; 21) (37).

Conclusion

We show that similarities and differences with other studies around the world such as age of our patients, high frequency of AML M2 and M4, relatively higher female rate of patients and common incidence of t (8; 21), apart from our small sample size, could be evidence of ethnic or geographic factors on different patterns of leukemia patients. Immunophenotypic results of our t (8; 21) positive patients had complete specific expression of CD45, CD34, CD38, CD33 and HLA-DR with 50% expression of CD19. This may help rapid decision making of cytogenetic analysis selection for these patients in the future. However, comprehensive cohort studies with higher numbers of patients with more detailed translocation analysis are recommended.

Acknowledgments

W Authors would like to thank the Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran for supporting this project (NO: 5/74/986, which was a part of the MSc thesis NO: 92/2-2/2). We also would like to thank all the colleagues in the Blood Transfusion Organization (Tabriz-Iran) where basic analysis was done and all the colleagues in Shahid Ghazi hospital especially Mr. Rasoul Chapari, our experienced technologist for performing our tests with the Auto analyzer H1. We are also grateful to Mr. Shahriar Afshin for helping in English editing. The authors have no conflicts of interest.

References

1. Roukos V, Mistelli T. The biogenesis of chromosome translocations. Nat Cell Biol. 2014; 16(4): 293-300.
2. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007; 7(4): 233-245.
3. Chung NG, Buchrozer-Ausch V, Radich JP. The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens. 2006; 68(5): 371-385.
4. Haurtin GS, Karp JE. Minimal residual disease in acute myeloid leukemia. Nat Rev Clin Oncol. 2013; 10(8): 460-471.
5. Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2011; 2(2): 95-107.
6. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014.
7. Mrozek K, Bloomfield CD. Clinical significance of the most common chromosome translocations in adults with acute myeloid leukemia. J Natl Cancer Inst Monogr. 2008; (39): 52-57.
8. Martens JH, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010; 584(12): 2662-2669.
9. Ferrara F, Del Vecchio L. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. Haematologica. 2002; 87(3): 306-319.
10. Dong HY, Kung JX, Bhakuni V, McGill J. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. Am J Clin Pathol. 2011; 135(1): 76-84.
11. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011; 29(5): 495-503.
12. Avery A. Molecular diagnostics of hematologic malignancies. Top Companion Anim Med. 2009; 24(3): 144-150.
13. Berker-Karazuum S, Mangouoglou AE, Nail Y, Yakut S, Sarain C F, Alper A, et al. Molecular diagnosis of hematological malignancies by RT-PCR. TJC. 2005; 35(3): 113-118.
14. Olesen LH, Clausen N, Dimitrijevic A, Kermoed G, Kjeldsen E, Hokland P. Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukemia: a single-laboratory study of 390 paediatric and adult patients. Br J Haematol. 2004; 127(1): 59-66.
15. Cho YU, Chi HS, Park CJ, Jang S, Seo EJ. Rapid detection of prognostically significant fusion transcripts in acute leukemia using simplified multiplex reverse transcription polymerase chain reaction. J Korean Med Sci. 2012; 27(10): 1155-1161.
16. Pakakasama S, Kajanachumpol S, Kanjanapongkul S, Sirachainan N, Meekaewkunchorn A, Ningsanond V, et al. Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia. Int J Lab Hema tol. 2008; 30(4): 286-291.
17. Andersson A, Höglund M, Johansson B, Lassen C, Billström R, Garwicz S, et al. Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies. Leukemia. 2001; 15(8): 1293-300.
18. Walter K, Cockerill PN, Barlow R, Clarke D, Hoogenkamp MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937-951.
19. Moser K, Schenkel D, Hoffmann C F, Alper A, et al. Molecular diagnosis of hematologic malignancies by RT-PCR. TJC. 2005; 35(3): 113-118.
20. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006; 368(9550): 1894-1907.
21. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937-951.
22. Mrozek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol. 2000; 72(3): 261-271.
23. Nakase K, Bradstock K, Sartor M, Gottlieb D, Byth K, Kita K, et al. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia. 2000; 14(1): 163-166.
24. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005; 19(5): 767-775.

25. Dastgiri S, Fozounkhah S, Shokrgozar S, Taghavinia M, Asvadi Kermani A. Incidence of leukemia in the Northwest of Iran. Health Promot Perspect. 2011; 1(1): 50-53.

26. Meng CY, Noor PJ, Ismail A, Ahid MF, Zakaria Z. Cytogenetic profile of de novo acute myeloid leukemia patients in Malaysia. Int J Biomed Sci. 2013; 9(1): 26-32.

27. Phelkoo KJ, Richards MA, Meller H, Schey SA, South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2,112 adult patients in Southeast England. Haematologica. 2006; 91(10): 1400-1404.

28. Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol. 2005; 84(12): 785-791.

29. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood. 2002; 100(13): 4325-4336.

30. Cheng Y, Wang Y, Wang H, Chen Z, Lou J, Xu H, et al. Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia. 2009; 23(10): 1801-1806.

31. Tien HF, Wang CH, Lee FY, Chuang SM, Chen YC, Lin DT, et al. Chromosomes studies on 30 Chinese patients with acute nonlymphocytic leukemia in Taiwan. Cancer Genet Cytogenet. 1988; 32(1): 101-108.

32. Koo SH, Kwon GC, Chun HJ, Park JW. Cytogenetic and fluorescence in situ hybridization analyses of hematologic malignancies in Korea. Cancer Genet Cytogenet. 1998; 101(1): 1-6.

33. Chan LC, Kwong YL, Liu HW, Chan TK, Todd D, Ching LM. Cytogenetic analysis of hematologic malignancies in Hong Kong: A study of 98 cases. Cancer Genet Cytogenet. 1992; 58(2): 154-159.

34. Rosline H, Narazah MY, Illunihayati I, Isa MN, Baba AA. The detection of AML1/ETO fusion transcript in acute myeloid leukaemia in Universiti Sains Malaysia Hospital. AsiaPac J Mol Biol Biotechnol. 2004; 12(1, 2): 49-52.

35. Ghazaey Zidanloo S, Hosseinzaeh Colagar A. Geographic heterogeneity of the AML1-ETO fusion gene in Iranian patients with acute myeloid leukemia. Rep Biochem Mol Biol. 2014; 3(1): 7-13.

36. Movafagh A, Isfahani F, Attarian H, Ghadiani M, Mosavi Jarahi A, Mohagheghi M. Specific chromosomal abnormalities in patients with acute nonlymphocytic leukemia from the Islamic Republic of Iran. Asian Pac J Cancer Prev. 2006; 7(3): 447-450.

37. Ray D, Kwon SY, Tagoh H, Heidenreich O, Ptasinska A, Bonifer C. Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression. Blood. 2013; 122(5): 759-769.